Susquehanna Fundamental Investments LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Susquehanna Fundamental Investments LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,301,772 shares of the biopharmaceutical company's stock, valued at approximately $34,536,000. Pfizer makes up 0.5% of Susquehanna Fundamental Investments LLC's portfolio, making the stock its 26th biggest position.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Passumpsic Savings Bank grew its position in shares of Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock valued at $743,000 after purchasing an additional 1,998 shares during the period. Virtu Financial LLC acquired a new stake in Pfizer in the 3rd quarter worth about $1,499,000. Westside Investment Management Inc. grew its holdings in Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock valued at $404,000 after buying an additional 1,004 shares during the period. Diamant Asset Management Inc. increased its stake in shares of Pfizer by 8.4% during the 3rd quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 660 shares during the last quarter. Finally, Morse Asset Management Inc purchased a new position in shares of Pfizer during the 3rd quarter worth about $2,649,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.7 %

Pfizer stock traded up $0.17 during midday trading on Friday, hitting $22.95. 35,816,572 shares of the stock were exchanged, compared to its average volume of 40,530,268. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a 50 day moving average price of $24.58 and a two-hundred day moving average price of $25.92. The firm has a market cap of $130.16 billion, a P/E ratio of 16.28, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company's revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.49%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 121.99%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.